公开(公告)号：US20240058438A1

公开(公告)日：2024-02-22

申请号：US18099035

申请日：2023-01-19

Applicant: The Governors of the University of Alberta ,  Helmholtz Center for Infection Research

Inventor： Michael Houghton ,  Abdolamir Landi ,  Carlos A. Guzman ,  Thomas Ebensen ,  Darren Hockman ,  John L. Law ,  Michael Logan

IPC: A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  A61K39/12 ,  C07K14/005 ,  A61K39/39 ,  C01F11/02 ,  C07D323/00 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86

CPC classification number: A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  A61K39/12 ,  C07K14/005 ,  A61K39/39 ,  C01F11/02 ,  C07D323/00 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86 ,  A61K2039/543

Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US20230310590A1

公开(公告)日：2023-10-05

申请号：US18099044

申请日：2023-01-19

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC: A61K39/29 ,  A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  A61P31/04 ,  A61K39/295 ,  C12N15/861

CPC classification number: A61K39/29 ,  A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  A61P31/04 ,  A61K39/295 ,  C12N15/861 ,  C07K2319/00 ,  C12N2770/24234 ,  A61K2039/55544

Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US20230098265A1

公开(公告)日：2023-03-30

申请号：US17702231

申请日：2022-03-23

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  Darren Hockman ,  John L. Law ,  Michael Logan ,  D. Lorne Tyrrell

IPC: A61K39/29 ,  A61K39/12

Abstract: The present disclosure provides immunogenic compositions comprising HCV E1, E2, or E1/E2 polypeptides from two or more different HCV genotypes. The present disclosure provides immunogenic compositions comprising HCV E2 or E1/E2 polypeptides from two or more different HCV genotypes. The immunogenic compositions are useful in carrying out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.

公开(公告)号：US10881726B2

公开(公告)日：2021-01-05

申请号：US16336732

申请日：2017-10-05

Applicant: The Governors of the University of Alberta ,  Helmholtz Center for Infection Research

Inventor： Michael Houghton ,  Abdolamir Landi ,  Carlos A. Guzman ,  Thomas Ebensen ,  Darren Hockman ,  John L. Law ,  Michael Logan

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  A61K31/675 ,  A61K39/095 ,  A61K39/29 ,  A61P31/14 ,  A61P37/04 ,  C07K14/005 ,  C01F11/02 ,  C07D323/00 ,  C07K14/18 ,  C07K14/28 ,  C07K14/33 ,  C07K14/34 ,  C12N15/86

Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US20220226335A1

公开(公告)日：2022-07-21

申请号：US17605194

申请日：2020-04-23

Applicant: The Governors of the University of Alberta

Inventor： Jack Jhamandas ,  Wen Fu ,  Ryoichi Kimura ,  D. Lorne Tyrrell ,  Ana Clementin ,  Kamlesh Sahu ,  Alexandr Belovodskiy ,  Mostofa Hena ,  Bing Bai ,  Appan Srinivas Kandadai ,  James A. Nieman ,  Michael Houghton

IPC: A61K31/538 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/5513 ,  A61P25/28

Abstract: The present disclosure provides non-peptidic heterocycle-containing amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.

公开(公告)号：US11324818B2

公开(公告)日：2022-05-10

申请号：US16334683

申请日：2017-09-21

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Darren Hockman ,  Chao Chen

IPC: A61K39/29 ,  A61K39/12 ,  A61K39/00

Abstract: The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

公开(公告)号：US20220105175A1

公开(公告)日：2022-04-07

申请号：US17511177

申请日：2021-10-26

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  Abdolamir Landi ,  Michael Logan ,  John L. Law ,  Darren Hockman ,  Chao Chen

IPC: A61K39/29 ,  A61K39/12

Abstract: The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

公开(公告)号：US10881727B2

公开(公告)日：2021-01-05

申请号：US16374403

申请日：2019-04-03

Applicant: The Governors of the University of Alberta

Inventor： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC: A61K39/00 ,  C07K16/28 ,  A61K39/21 ,  A61K48/00 ,  C12N15/86 ,  A61K39/29 ,  A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  A61P31/04 ,  A61K39/295 ,  C12N15/861

Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

公开(公告)号：US10550171B2

公开(公告)日：2020-02-04

申请号：US14443630

申请日：2013-11-21

Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

Inventor： Adrian Egli ,  Deanna Michelle Santer ,  Aviad Yaagov Levin ,  Bradley Scott Thomas ,  Khaled Hassan Sayed Barakat ,  Michael A. Joyce ,  Daire Thomas O'Shea ,  Rakesh Kumar Bhat ,  Michael Houghton ,  D. Lorne J. Tyrrell ,  Atul Humar ,  Deepali Kumar

IPC: C07K14/00 ,  C07K14/715 ,  C07K16/28 ,  A61K39/12 ,  A61K39/39 ,  A61K39/145 ,  A61K39/245 ,  C07K14/57 ,  C12N7/00 ,  A61K39/00

Abstract: The present disclosure provides peptides that modulate an immune response in an individual. The present disclosure provides peptides that modulate cellular responses in vitro. The present disclosure provides compositions comprising the peptides. The peptides and compositions are useful in methods of modulating an immune response in an individual, which methods are also provided.

公开(公告)号：US20180169219A1

公开(公告)日：2018-06-21

申请号：US15574427

申请日：2016-07-06

Applicant: THE GOVERNORS OF THE UNIVERSITY OF ALBERTA

Inventor： Michael Houghton ,  John L. Law ,  Michael Logan ,  Darren Hockman ,  Abdolamir Landi

IPC: A61K39/29 ,  A61K39/295 ,  C12N15/861 ,  A61P31/14 ,  A61P31/04 ,  A61P37/04

CPC classification number: A61K39/29 ,  A61K39/12 ,  A61K39/295 ,  A61K2039/55544 ,  A61P31/04 ,  A61P31/14 ,  A61P37/04 ,  C07K2319/00 ,  C12N15/861 ,  C12N2770/24234

Abstract: The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.